

Bilenker Joshua H.
Form 4
December 18, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bilenker Joshua H.

2. Issuer Name and Ticker or Trading Symbol
Loxo Oncology, Inc. [LOXO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O LOXO ONCOLOGY, INC., 281
TRESSER BOULEVARD, 9TH
FLOOR

3. Date of Earliest Transaction
(Month/Day/Year)
12/14/2017

Director 10% Owner
 Officer (give title below) Other (specify below)
President & CEO

(Street)
STAMFORD, CT 06901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	12/14/2017		M ⁽¹⁾		7,500 A \$ 1.184	D	
Common Stock	12/14/2017		S ⁽¹⁾		2,600 D \$ 82.5465	D	
Common Stock	12/14/2017		S ⁽¹⁾		2,900 D \$ 83.4179	D	
Common Stock	12/14/2017		S ⁽¹⁾		2,000 D \$ 84.2935	D	

Edgar Filing: Bilenker Joshua H. - Form 4

(5)

Common Stock	12/15/2017	M ⁽¹⁾	7,500	A	\$ 1.184	190,207	D
Common Stock	12/15/2017	S ⁽¹⁾	700 ⁽²⁾	D	\$ 76.9271	189,507	D
Common Stock	12/15/2017	S ⁽¹⁾	2,268 ⁽²⁾	D	\$ 78.0645	187,239	D
Common Stock	12/15/2017	S ⁽¹⁾	3,023 ⁽²⁾	D	\$ 78.9932	184,216	D
Common Stock	12/15/2017	S ⁽¹⁾	609 ⁽²⁾	D	\$ 80.0822	183,607	D
Common Stock	12/15/2017	S ⁽¹⁾	600 ⁽²⁾	D	\$ 80.8817	183,007	D
Common Stock	12/15/2017	S ⁽¹⁾	100	D	\$ 81.72	182,907	D
Common Stock	12/15/2017	S ⁽¹⁾	200	D	\$ 82.86	182,707	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock	\$ 1.184	12/14/2017		M ⁽¹⁾	7,500	⁽¹¹⁾ 11/14/2023	Common Stock	7,500

Edgar Filing: Bilenker Joshua H. - Form 4

Represents the weighted average sales price per share. The shares sold at prices ranging from \$79.63 to \$80.50 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

(10) Represents the weighted average sales price per share. The shares sold at prices ranging from \$80.67 to \$81.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

(11) The stock option is immediately exercisable in full, and vests as to 25% of the shares subject to the option on the one-year anniversary of the vesting commencement date, and thereafter as to 1/48th of the shares in equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.